AM 36Alternative Names: AM36
Latest Information Update: 31 Aug 2004
At a glance
- Originator Zenyth Therapeutics
- Class Neuroprotectants
- Mechanism of Action Antioxidants; Sodium channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Stroke